HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.

Abstract
Resistance of fibrin-bound thrombin to inactivation by the heparin/antithrombin III complex is considered a limitation in the use of heparin as an antithrombotic agent. Intimatan (dermatan 4,6-di-O-sulfate) is a heparin cofactor II agonist that inhibits both free and bound forms of thrombin. The present study examines the hypothesis that Intimatan prevents thrombotic occlusion in response to vascular wall injury in a canine model of carotid artery/jugular vein thrombosis. The left carotid artery and right jugular vein served as vehicle-treated control vessels, whereas the right carotid artery and left jugular vein were subjected to electrolytic injury after administration of Intimatan (9 mg/kg bolus + 300 microg/kg/min infusion, i.v.) or dalteparin (Fragmin) (400 IU/kg, s.c.). Intimatan significantly increased time to carotid artery (226.0 +/- 14.0 min) and jugular vein (240.0 +/- 0.0 min) thrombosis, compared with control vessels (carotid artery, 87.1 +/- 7.9 min; jugular vein, 60.6 +/- 7.4 min). Vessel patency was maintained in eight of eight jugular veins and seven of eight carotid arteries during treatment with Intimatan. Dalteparin significantly increased time to carotid artery thrombosis (122.1 +/- 17.5 min) compared with control (64.3 +/- 8.2 min), but did not change the time to thrombosis in the jugular vein. Only one carotid artery remained patent at the end of the dalteparin protocol. The two drugs produced minimal increases in bleeding times, and Intimatan increased the activated partial thromboplastin time above that observed with dalteparin. The results demonstrate that Intimatan is effective in preventing occlusive arterial and venous thrombosis in an experimental model of deep vascular wall injury.
AuthorsJames K Hennan, Ting-Ting Hong, Ardamanpal K Shergill, Edward M Driscoll, Alan D Cardin, Benedict R Lucchesi
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 301 Issue 3 Pg. 1151-6 (Jun 2002) ISSN: 0022-3565 [Print] United States
PMID12023550 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antithrombins
  • intimatan
  • Dermatan Sulfate
Topics
  • Animals
  • Antithrombins (administration & dosage, therapeutic use)
  • Bleeding Time
  • Carotid Arteries (physiopathology)
  • Carotid Artery Thrombosis (drug therapy, physiopathology, prevention & control)
  • Constriction, Pathologic (drug therapy, physiopathology)
  • Dermatan Sulfate (administration & dosage, analogs & derivatives, therapeutic use)
  • Disease Models, Animal
  • Dogs
  • Injections, Intravenous
  • Jugular Veins (pathology)
  • Platelet Aggregation (drug effects)
  • Venous Thrombosis (drug therapy, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: